collection
https://read.qxmd.com/read/38932668/selecting-postoperative-adjuvant-systemic-therapy-for-early-stage-breast-cancer-an-updated-assessment-and-systematic-review-of-leading-commercially-available-gene-expression-assays
#1
REVIEW
David M Hyams, Avital Bareket-Samish, Juan Enrique Bargallo Rocha, Sebastian Diaz-Botero, Sandra Franco, Debora Gagliato, Henry L Gomez, Ernesto Korbenfeld, Gabriel Krygier, Andre Mattar, Aníbal Nuñez De Pierro, Manuel Ruiz Borrego, Cynthia Villarreal
Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit...
June 24, 2024: Journal of Surgical Oncology
https://read.qxmd.com/read/38886818/association-of-early-menarche-with-breast-tumor-molecular-features-and-recurrence
#2
JOURNAL ARTICLE
Alexandra R Harris, Tengteng Wang, Yujing J Heng, Gabrielle M Baker, Phuong Anh Le, Jun Wang, Christine Ambrosone, Adam Brufsky, Fergus J Couch, Francesmary Modugno, Christopher G Scott, Celine M Vachon, Susan E Hankinson, Bernard A Rosner, Rulla M Tamimi, Cheng Peng, A Heather Eliassen
BACKGROUND: Early menarche is an established risk factor for breast cancer but its molecular contribution to tumor biology and prognosis remains unclear. METHODS: We profiled transcriptome-wide gene expression in breast tumors (N = 846) and tumor-adjacent normal tissues (N = 666) from women in the Nurses' Health Studies (NHS) to investigate whether early menarche (age < 12) is associated with tumor molecular and prognostic features in women with breast cancer...
June 17, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38886328/guideline-concordant-surgical-care-for-lobular-versus-ductal-inflammatory-breast-cancer
#3
JOURNAL ARTICLE
Yoshiko Iwai, Stephany Perez-Rojas, Samantha M Thomas, Audree B Tadros, Steven G Woodward, Jennifer Q Zhang, Leisha C Elmore, Gary M Freedman, Julia C Tchou, Aaron D Bleznak, Oluwadamilola M Fayanju
INTRODUCTION: Quality of surgical care is understudied for lobular inflammatory breast cancer (IBC), which is less common, more chemotherapy-resistant, and more mammographically occult than ductal IBC. We compared guideline-concordant surgery (modified radical mastectomy [MRM] without immediate reconstruction following chemotherapy) for lobular versus ductal IBC. METHODS:  Female individuals with cT4dM0 lobular and ductal IBC were identified in the National Cancer Database (NCDB) from 2010-2019...
June 17, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38837063/research-gaps-in-sentinel-lymph-node-biopsy-in-breast-cancer
#4
JOURNAL ARTICLE
Omar Hamdy
No abstract text is available yet for this article.
June 5, 2024: Oncologist
https://read.qxmd.com/read/38845078/epidemiology-of-early-vs-late-recurrence-among-women-with-early-stage-estrogen-receptor-positive-breast-cancer-in-the-pathways-study
#5
JOURNAL ARTICLE
Alfredo V Chua, Haiyang Sheng, Emily Liang, Shipra Gandhi, Marilyn L Kwan, Isaac J Ergas, Janise M Roh, Cecile A Laurent, Li Yan, Thaer Khoury, Christine B Ambrosone, Lawrence H Kushi, Song Yao
BACKGROUND: Relatively little is known about the differences in prognostic factors for early vs late recurrence among women with early-stage estrogen receptor-positive (ER+) breast cancer. METHODS: We analyzed factors related to early (<5 years) vs late (≥5 years) recurrence in 2,992 women with stage I-IIB ER+ breast cancer in the Pathways Study, a prospective cohort of women with breast cancer enrolled between 2006 and 2013, with ascertainment of recurrence and death through December 2021...
June 6, 2024: Journal of the National Cancer Institute
https://read.qxmd.com/read/38837150/early-implementation-of-exercise-to-facilitate-recovery-after-breast-cancer-surgery-a-randomized-clinical-trial
#6
JOURNAL ARTICLE
Jihee Min, Jee Ye Kim, Jiin Ryu, Seho Park, Kerry S Courneya, Jennifer Ligibel, Seung Il Kim, Justin Y Jeon
IMPORTANCE: Recovery of shoulder function following breast cancer surgery is crucial for physical functioning and quality of life. While early implementation of shoulder rehabilitation exercises may enhance recovery, the optimal timing and exercise program remain unclear. OBJECTIVE: To investigate whether an early exercise intervention, initiated 1 day postsurgery and continued for 1 month through subsequent visits, could improve shoulder range of motion (ROM) and strength in patients with breast cancer...
June 5, 2024: JAMA Surgery
https://read.qxmd.com/read/38801441/predictive-value-of-pretreatment-circulating-inflammatory-response-markers-in-the-neoadjuvant-treatment-of-breast-cancer-meta-analysis
#7
JOURNAL ARTICLE
Gavin P Dowling, Gordon R Daly, Aisling Hegarty, Sandra Hembrecht, Aisling Bracken, Sinead Toomey, Bryan T Hennessy, Arnold D K Hill
BACKGROUND: Systemic inflammatory response markers have been found to have a prognostic role in several cancers, but their value in predicting the response to neoadjuvant chemotherapy in breast cancer is uncertain. A systematic review and meta-analysis of the literature was carried out to investigate this. METHODS: A systematic search of electronic databases was conducted to identify studies that explored the predictive value of circulating systemic inflammatory response markers in patients with breast cancer before commencing neoadjuvant therapy...
May 3, 2024: British Journal of Surgery
https://read.qxmd.com/read/38809304/does-structural-racism-impact-receipt-of-nccn-guideline-concordant-breast-cancer-treatment
#8
JOURNAL ARTICLE
Maya Lubarsky, Alexandra E Hernandez, Brianna L Collie, Ashly C Westrick, Cheyenne Thompson, Susan B Kesmodel, Neha Goel
PURPOSE: Disparities in breast cancer survival remain a challenge. We aimed to analyze the effect of structural racism, as measured by the Index of Concentration at the Extremes (ICE), on receipt of National Cancer Center Network (NCCN) guideline-concordant breast cancer treatment. METHODS: We identified patients treated at two institutions from 2005 to 2017 with stage I-IV breast cancer. Census tracts served as neighborhood proxies. Using 5-year estimates from the American Community Survey, 5 ICE variables were computed to create 5 models, controlling for economic segregation, non-Hispanic Black (NHB) segregation, NHB/economic segregation, Hispanic segregation, and Hispanic/economic segregation...
May 29, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38773037/understanding-patient-experiences-to-inform-future-studies-to-optimize-personalization-of-treatment-for-early-breast-cancer
#9
JOURNAL ARTICLE
Stuart A McIntosh, Mhairi Mactier, Katherine Fairhurst, Jacqui Gath, Hilary Stobart, Shelley Potter
BACKGROUND: Breast cancer treatment is multimodal, but not all patients benefit from each treatment, and many experience morbidities significantly impacting quality of life. There is increasing interest in tailoring breast cancer treatments to optimize oncological outcomes and reduce treatment burden, but it is vital that future trials focus on treatments that most impact patients. This study was designed to explore patient experiences of treatment to inform future research. METHODS: An online survey was co-developed with patient advocates to explore respondents' experiences of breast cancer treatment...
May 21, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38759577/diagnostic-accuracy-of-intraoperative-methods-for-margin-assessment-in-breast-cancer-surgery-a-systematic-review-meta-analysis
#10
REVIEW
Gavin P Dowling, Cian M Hehir, Gordon R Daly, Sandra Hembrecht, Stephen Keelan, Katie Giblin, Maen M Alrawashdeh, Fiona Boland, Arnold D K Hill
PURPOSE: There are a wide variety of intraoperative techniques available in breast surgery to achieve low rates for positive margins of excision. The objective of this systematic review was to determine the pooled diagnostic accuracy of intraoperative breast margin assessment techniques that have been evaluated in clinical practice. METHODS: This study was performed in accordance with PRISMA guidelines. A systematic search of the literature was conducted to identify studies assessing the diagnostic accuracy of intraoperative margin assessment techniques...
May 10, 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38404967/management-of-neuroendocrine-breast-carcinoma-nebc-review-of-literature
#11
REVIEW
A Mohamed, J Zeidalkilani, S L Asa, M Trybula, Alberto J Montero
Extra pulmonary high-grade poorly differentiated neuroendocrine carcinomas (EP-NECs) are rare tumors that usually arise in the gastrointestinal and genitourinary tracts. Primary neuroendocrine carcinoma of the breast (NEBC) is extremely rare, representing less than 0.1% of all breast cancers and less than 1% of neuroendocrine neoplasms. Consequently, they can be misdiagnosed as other types of breast cancer, however, proper immunohistochemical (IHC) studies can assist with making the correct diagnosis. Management of NEBC can be challenging given the paucity of evidence-based literature and should not routinely follow the therapeutic guidelines of other breast cancers...
2024: Oncology Reviews
https://read.qxmd.com/read/38634039/identification-and-validation-of-novel-metastasis-related-immune-gene-signature-in-breast-cancer
#12
JOURNAL ARTICLE
Shen Ma, Ran Hao, Yi-Wei Lu, Hui-Po Wang, Jie Hu, Yi-Xin Qi
BACKGROUND: Distant metastasis remains the leading cause of death among patients with breast cancer (BRCA). The process of cancer metastasis involves multiple mechanisms, including compromised immune system. However, not all genes involved in immune function have been comprehensively identified. METHODS: Firstly 1623 BRCA samples, including transcriptome sequencing and clinical information, were acquired from Gene Expression Omnibus (GSE102818, GSE45255, GSE86166) and The Cancer Genome Atlas-BRCA (TCGA-BRCA) dataset...
2024: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38717543/-peace-of-mind-after-mastectomy-a-scoping-review
#13
JOURNAL ARTICLE
Safraz A Hamid, Baylee Bakkila, Kurt S Schultz, Alyssa A Grimshaw, Craig G Gunderson, Elizabeth L Godfrey, Clara Lee, Elizabeth Berger, Shoshana Rosenberg, Rachel A Greenup
BACKGROUND: Many women eligible for breast conservation therapy (BCT) elect unilateral mastectomy (UM) with or without contralateral prophylactic mastectomy (CPM) and cite a desire for "peace of mind." This study aimed to characterize how peace of mind is defined and measured and how it relates to surgical choice. METHODS: Nine databases were searched for relevant articles through 8 October 2023, and data were extracted from articles meeting the inclusion criteria...
May 8, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38657322/enhancing-clinical-decision-support-with-genomic-tools-in-breast-cancer-a-scottish-perspective
#14
JOURNAL ARTICLE
A L Peters, P S Hall, L B Jordan, F Y Soh, L Hannington, S Makaranka, G Urquhart, M Vallet, D Cartwright, H Marashi, B Elsberger
INTRODUCTION: The Oncotype DX Breast RS test has been adopted in Scotland and has been the subject of a large population-based study by a Scottish Consensus Group to assess the uptake of the recurrence score (RS), evaluate co-variates associated with the RS and to analyse the effect it may have had on clinical practice. MATERIALS & METHODS: Pan-Scotland study between August 2018-August 2021 evaluating 833 patients who had a RS test performed as part of their diagnostic pathway...
June 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38608530/platinum-dose-in-neoadjuvant-therapy-for-triple-negative-breast-cancer-a-systematic-review-and-network-meta-analysis
#15
REVIEW
Fausto Petrelli, Antonio Ghidini, Carmen Rea, Maria Chiara Parati, Karen Borgonovo, Michele Ghidini, Fiorella Ruatta, Alberto Zaniboni, Andrea Luciani, Ornella Garrone, Gianluca Tomasello
INTRODUCTION: There are multiple neoadjuvant regimens, including platinum agents for triple-negative breast cancer (TNBC), each with a different safety profile, outcome, and pathologic complete response rate (pCR%). We performed a systematic review and network meta-analysis to compare the efficacy and safety of different platinum-based neoadjuvant CT treatments for TNBC. METHODS: Bibliographic databases (PubMed, Embase, and Cochrane Library) were searched from their inception to October 31, 2022...
April 11, 2024: Current Problems in Cancer
https://read.qxmd.com/read/38531689/systematic-review-of-targeted-axillary-dissection-in-node-positive-breast-cancer-treated-with-neoadjuvant-systemic-therapy-variation-in-type-of-marker-and-timing-of-placement
#16
JOURNAL ARTICLE
Sabine R de Wild, Linetta B Koppert, Thiemo J A van Nijnatten, Loes F S Kooreman, Marie-Jeanne T F D Vrancken Peeters, Marjolein L Smidt, Janine M Simons
BACKGROUND: In node-positive (cN+) breast cancer treated with neoadjuvant systemic therapy, combining sentinel lymph node biopsy and targeted lymph node excision, that is targeted axillary dissection, increases accuracy. Targeted axillary dissection procedures differ in terms of the targeted lymph node excision technique. This systematic review aimed to provide an overview of targeted axillary dissection procedures regarding definitive marker type and timing of placement: before neoadjuvant systemic therapy (1-step procedure) or after neoadjuvant systemic therapy adjacent to a clip placed before the neoadjuvant therapy (2-step procedure)...
March 2, 2024: British Journal of Surgery
https://read.qxmd.com/read/38568368/brca1-2-mutation-carriers-vs-the-general-breast-cancer-population-n%C3%A2-%C3%A2-799-986-21-gene-assay-based-molecular-characterization
#17
JOURNAL ARTICLE
Rinat Yerushalmi, Adi Pomerantz, Ron Lewin, Shani Paluch-Shimon, Lior Soussan-Gutman, Frederick L Baehner, Hillary Voet, Avital Bareket-Samish, Inbal Kedar, Yael Goldberg, Tamar Peretz-Yablonski, Luna Kadouri
PURPOSE: We compared 21-gene recurrence score (RS) distribution and expression of the single-gene/gene groups within this assay between BC patients with pathogenic variants (PV) in BRCA1/2 vs the general 21-gene-tested BC population. METHODS: This retrospective study included consecutive 21-gene-tested female ER + HER2-negative BC patients with germline PVs in BRCA1/2. RS/gene expression data were compared to a previously described commercial use database (CDB, N = 799,986)...
April 3, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38564263/factors-influencing-adherence-to-the-risk-management-program-for-women-with-a-genetic-predisposition-to-breast-cancer-real-world-data-from-a-french-multicenter-program
#18
JOURNAL ARTICLE
Ke Zhou, Martine Bellanger, Louise Crivelli, Sandy Laham, Charlotte Huet, Caroline Abadie
BACKGROUND: Risk management programs targeting women with genetic predispositions to breast cancer (BC), eg, BRCA1 and BRCA2, are effective assuming full adherence with the program protocol. However, high risk to BC in women and equal access to care may not result in high and uniform adherence with the program. OBJECTIVE: To elucidate factors influencing adherence with screening program in women with genetic predispositions to BC. MATERIAL AND METHODS: We retrieved data from a multicenter pathogenic-related BC surveillance program across 4 French regions...
April 2, 2024: Oncologist
https://read.qxmd.com/read/38489166/use-of-axillary-ultrasound-to-guide-breast-cancer-management-in-the-genomic-assay-era
#19
JOURNAL ARTICLE
Geok Hoon Lim, John Carson Allen, Yien Sien Lee, Sze Yiun Teo, Li Ching Lau, Thida Win, Lester Chee Hao Leong
INTRODUCTION: Chemotherapy is conventionally offered to non-stage IV breast cancer patients with metastatic nodes. However, the RxPONDER trial showed that chemotherapy can be omitted in selected patients with 1-3 metastatic nodes if the 21-gene assay recurrence score is ≤25. We aimed to investigate if axillary ultrasound can identify this group of patients with limited nodal burden so that they can undergo upfront surgery followed by gene assay testing, to potentially avoid chemotherapy...
2024: Breast Disease
https://read.qxmd.com/read/38410761/standard-of-care-treatment-for-her2-metastatic-breast-cancer-and-emerging-therapeutic-options
#20
REVIEW
Sarah K Premji, Ciara C O'Sullivan
Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. Over the past 25 years, innovations in molecular biology, pathology, and early therapeutics have transformed the treatment landscape. With the advent of multiple HER2-directed therapies, there have been immense improvements in oncological outcomes in both adjuvant and metastatic settings. Currently, 8 HER2-targeted therapies are approved by the Food and Drug Administration (FDA) for the treatment of early-stage and/or advanced/metastatic disease...
2024: Breast Cancer: Basic and Clinical Research
label_collection
label_collection
6331
1
2
2024-03-20 20:09:07
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.